Decrease in breast density in the contralateral normal breast of patients receiving neoadjuvant chemotherapy: MR imaging evaluation

Radiology

Volumn 255, Issue 1, 2010, Pages 44-52

  Chen, Jeon Hor ^a,b   Nie, Ke ^a   Bahri, Shadfar ^a   Hsu, Chieh Chih ^b   Hsu, Fei Ting ^b   Shih, Han Ni ^b   Lin, Muqing ^a   Nalcioglu, Orhan ^a   Su, Min Ying ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; DRUG EFFECT; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CONTRAST MEDIA; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC; TAXOIDS; TREATMENT OUTCOME;

EID: 77950452352     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.09091090     Document Type: Article

References (40)

1. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17(2):460-469.
2. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16(8): 2672-2685.
3. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16(1):93-100.
4. Booser DJ, Hortobagyi GN. Treatment of locally advanced breast cancer. Semin Oncol 1992;19(3):278-285.
5. Singletary S, McNeese M, Hortobagyi GN. Feasibility of breast-conservation chemocancers, therapy for locally advanced breast carcinoma. Cancer 1992;69(11):2849-2852.
6. Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 2007;30(2):126-132.
7. Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005;104(8):1575-1579.
8. Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 2002;9(6):466-472.
9. Poikonen P, Saarto T, Elomaa I, Joensuu H, Blomqvist C. Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients. Eur J Cancer 2000;36(1):43-48.
10. Lee S, Kil WJ, Chun M, et al. Chemotherapy-related amenorrhea in premenopausal women with breast cancer. Menopause 2009;16(1):98-103.
11. Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007;110(10):2222-2229.
12. Gadducci A, Cosio S, Genazzani AR. Ovarian function and childbearing issues in breast cancer survivors. Gynecol Endocrinol 2007;23(11):625-631.
13. Swain SM, Land SR, Ritter MW, et al. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat 2009;113(2): 315-320.
14. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007;356(3):227-236.
15. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15(6):1159-1169.
16. Hill-Kayser CE, Harris EE, Hwang WT, Solin LJ. Twenty-year incidence and patterns of contralateral breast cancer after breast conservation treatment with radiation. Int J Radiat Oncol Biol Phys 2006;66(5):1313-1319.
17. Bremnes Y, Ursin G, Bjurstam N, Rinaldi S, Kaaks R, Gram IT. Endogenous sex hormones, prolactin and mammographic density in postmenopausal Norwegian women. Int J Cancer 2007;121(11):2506-2511.
18. Noh JJ, Maskarinec G, Pagano I, Cheung LW, Stanczyk FZ. Mammographic densities and circulating hormones: a cross-sectional study in premenopausal women. Breast 2006;15(1):20-28.
19. Harvey JA, Bovbjerg VE. Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology 2004;230(1):29-41.
20. Kopans DB. Basic physics and doubts about relationship between mammographically determined tissue density and breast cancer risk. Radiology 2008;246(2):348-353.
21. Nie K, Chen JH, Chan S, et al. Development of a quantitative method for analysis of breast density based on three-dimensional breast MRI. Med Phys 2008;35(12):5253-5262.
22. 1H MR spectroscopy. Radiology 2009;251(3):653-662.
23. Brisson J, Brisson B, CotéG, Maunsell E, BérubéS, Robert J. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 2000;9(9):911-915.
24. Atkinson C, Warren R, Bingham SA, Day NE. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 1999;8(10):863-866.
25. Son HJ, Oh KK. Significance of follow-up mammography in estimating the effect of tamoxifen in breast cancer patients who have undergone surgery. AJR Am J Roentgenol 1999;173(4):905-909.
26. Toledano A, Garaud P, Serin D, et al. Concurrent administration of adjuvant chemotherapy and radiotherapy after breastconserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study. Int J Radiat Oncol Biol Phys 2006;65(2):324-332.
27. Vachon CM, Pankratz VS, Scott CG, et al. Longitudinal trends in mammographic percent density and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16(5):921-928.
28. Vachon CM, Brandt KR, Ghosh K, et al. Mammographic breast density as a general marker of breast cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16(1):43-49.
29. Boyd NF, Martin LJ, Sun L, et al. Body size, mammographic density, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15(11):2086-2092.
30. Chen J, Pee D, Ayyagari R, et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 2006;98(17):1215-1226.
31. Santen RJ, Boyd NF, Chlebowski RT, et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer 2007;14(2):169-187.
32. Shahedi K, Emanuelsson M, Wiklund F, Gronberg H. High risk of contralateral breast carcinoma in women with hereditary/ familial non-BRCA1/BRCA2 breast carcinoma. Cancer 2006;106(6):1237-1242.
33. White E, Velentgas P, Mandelson MT, et al. Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. J Natl Cancer Inst 1998;90(12):906-910.
34. Ursin G, Parisky YR, Pike MC, Spicer DV. Mammographic density changes during the menstrual cycle. Cancer Epidemiol Biomarkers Prev 2001;10(2):141-142.
35. Buist DS, Aiello EJ, Miglioretti DL, White E. Mammographic breast density, dense area, and breast area differences by phase in the menstrual cycle. Cancer Epidemiol Biomarkers Prev 2006;15(11):2303-2306.
36. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Post-menopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95(1):30-37.
37. Marchesoni D, Driul L, Ianni A, et al. Post-menopausal hormone therapy and mammographic breast density. Maturitas 2006; 53(1):59-64.
38. Bremnes Y, Ursin G, Bjurstam N, Lund E, Gram IT. Different types of postmenopausal hormone therapy and mammographic density in Norwegian women. Int J Cancer 2007; 120(4):880-884.
39. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687-1717.
40. Cuzick J, Warwick J, Pinney L, et al. Change in breast density as a biomarker of breast cancer risk reduction: results from IBIS-I. Abstract 61. Presented at the 31st annual meeting of San Antonio Breast Cancer Symposium, San Antonio, Tex, December 10-14, 2008.